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ABSTRACT Aim: To investigate the cost of antibiotic resistance versus the potential for 9 
resistant clones to adapt in maintaining polymorphism for resistance. Materials & methods: 10 
Experimental evolution of Escherichia coli carrying different resistance alleles was performed 11 
under an environment devoid of antibiotics and evolutionary parameters estimated from their 12 
frequencies along time. Results & conclusion: Costly resistance mutations were found to 13 
coexist with lower cost resistances for hundreds of generations, contrary to the hypothesis that 14 
the cost of a resistance dictates its extinction. Estimated evolutionary parameters for the 15 
different resistance backgrounds suggest a higher adaptive potential of clones with costly 16 
antibiotic resistance mutations, overriding their initial cost of resistance and allowing their 17 
maintenance in the absence of drugs. 18 
 19 




Bacterial populations can acquire antibiotic resistance (AR) as a result of transfer and 24 
acquisition of new genetic material between individuals of the same or different species but 25 
also by chromosomal DNA mutations, which alter existing bacterial proteins. One landmark 26 
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example of this second process is provided by Mycobacterium tuberculosis (the etiologic agent 27 
of tuberculosis in humans), which albeit incapable of horizontal gene transfer can display “total 28 
drug resistance” [1]. This kind of resistance is typically acquired by the sequential accumulation 29 
of mutations that alter the cellular target for the drug action. During this process extensive clonal 30 
competition has also been observed [2]. Understanding how these AR determinants disseminate 31 
and are maintained in bacterial populations is therefore of paramount importance.  32 
Mutations that confer spontaneous AR can occur at relatively high rates [3]. For instance, 33 
rifampicin (Rif) resistance occurs spontaneously at frequencies that can be higher than 10-8 in 34 
wild isolates of E. coli [4]. In fact, the levels of resistance in pathogenic populations continue 35 
to rise at an alarming rate [5,6] having reached the same significance as any other virulence 36 
factor [7]. However, in the absence of the drug, AR mutations typically bear a cost [8-10]. This 37 
cost depends on the specific resistance allele [11], on the environment [12,13] and on the 38 
genomic background where the mutation happens to arise [14,15]. Nevertheless, suppressive 39 
mutations that mitigate this cost can occur either in the presence or absence of antibiotics. In 40 
the absence of drugs, one can expect that sensitive bacteria, will sweep through the population, 41 
driving the AR mutant to extinction. However, more often than not, resistant strains have been 42 
observed to acquire additional beneficial mutations that reduce the costs of resistance without 43 
loss of resistance, thus preventing the elimination of resistance alleles [16]. These 44 
compensatory mutations are common in clinical isolates [17,18] and hinder the possibility of 45 
reverting the resistance mutation, due to their epistatic nature [19]. Since the probability of a 46 
compensatory mutation tends to be much higher than that of reversion for several resistance 47 
mutations [10,20-23], it is likely that resistance alleles may take long periods of time to be 48 
eliminated from populations.  49 
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Many mutations that confer AR occur in essential genes and are likely to result in pleiotropic 50 
effects altering several bacterial traits. Important examples include resistance to Rif and 51 
streptomycin (Str) [24,25]. Rif is one of the frontline anti-tuberculosis drugs [26]. The co-52 
occurrence of resistance to this antibiotic and isoniazid typically classifies M. tuberculosis as 53 
multi-drug-resistant. These are the two most commonly used and effective drugs for the 54 
treatment of tuberculosis. The main genetic target for Rif resistance is rpoB, which codes for 55 
the β subunit of the RNA polymerase. Besides typically decreasing the rate of transcription and 56 
consequently the growth rate, rpoB resistance mutations are probably some of the most 57 
pleiotropic among AR mutations. Their effects can range from regulation of competence, 58 
sporulation and germination in Bacillus subtilis [27], temperature and phage sensitivity in E. 59 
coli [28], growth advantage in stationary phase in E. coli and Salmonella enterica [29], 60 
increased antibiotic resistance in Staphylococcus aureus [30,31], amongst others (see [26] for 61 
a review). rpoA and rpoC, as well as additional mutations in rpoB, have been pointed as targets 62 
for compensatory mutation relieving the deleterious effects of rpoB Rif resistance mutations in 63 
M. tuberculosis, S. enterica and E. coli [17,32-34]. Another frequent resistance is Str, occurring 64 
through mutations in the rpsL gene, which codes for the S12 subunit of the ribosome 65 
compromising translational speed and accuracy. Compensatory mutations for Str resistance 66 
have been observed in Salmonella thyphimurium, and some of the target genes include rpsL, 67 
rpsD, rpsE and rplS [12,35,36], which encode the ribosomal subunits S12, S4, S5 and L19. 68 
Recent analysis of 161 genomes of M. tuberculosis with a broad range of resistance profiles, 69 
revealed seven possible additional targets for compensatory mutations to Str resistance [37].  70 
Given such broad targets for increasing the fitness of AR mutants we may expect that these 71 
resistances change the evolvability of bacteria, through altering the range of beneficial 72 
mutations that can be accessed by a given resistance genotype. Here we use the term 73 
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evolvability as “the genome’s ability to produce adaptive variants” [38]. In this sense, a costly 74 
AR mutant may be able to effectively compete with a less costly resistance allele (i.e., with a 75 
higher selective coefficient when in direct competition) if the evolvability of the former is 76 
higher. The conditions for this to happen will depend on the distribution of effects of beneficial 77 
mutations (DEBM), as well as on the rate of beneficial mutations available to each genotype 78 
[22,39,40].  79 
Most studies addressing the competitive fitness effects associated with AR, consider resistant 80 
strains competing with the ancestral sensitive strain. However, in many natural environments 81 
the frequency of resistance can be very high and competition between different resistant alleles 82 
may be a common event [2,37,41-45]. For instance in [2], a monoclonal Mycobacterium 83 
tuberculosis infection was followed and both clonal sweeps and the coexistence of different 84 
resistant mutants were observed in the dynamics of the population. Competition between 85 
different resistant strains is also likely to occur whenever there is spatial heterogeneity, with 86 
different areas posing different selective pressures [2,46,47]. Furthermore, bacteria with 87 
multiple resistance alleles are also commonly segregating in natural populations [48-50]. This 88 
competitive context might therefore play a crucial role in the maintenance of antibiotic 89 
resistance. 90 
Here we study the process of fitness recovery mimicking an environment with different 91 
resistance backgrounds competing at high frequency. We use an experimental evolution 92 
approach [51] to test the ability of clones with costly AR alleles to coexist or even outcompete 93 
clones with less costly resistances. In a drug free environment, the differences in the fitness 94 
costs of resistance alleles should determine their probability of extinction. Contrary to this 95 
simple expectation, we observe the maintenance of costly resistance alleles over hundreds of 96 
generations even when their fitness impairment should predict fast extinction. We infer that 97 
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differences in adaptive potential for each AR mutant exist and suggest that these can explain 98 
the observed outcomes in the evolution of resistance. 99 
 100 
MATERIALS AND METHODS 101 
Bacterial strains and growth conditions 102 
All bacterial strains used in this study were derived from Escherichia coli K12 MG1655 and 103 
have in common the following genotype: galK::yfp/cfp cmR (pKD3), ΔlacIZYA.  The yellow 104 
(yfp) and cyan (cfp) alleles were integrated at the galK locus under the control of the lac 105 
promoter and were constructed by P1 transduction[52] of yfp/cfp inserts from previously 106 
constructed strains [53].  In these strains the fluorescence marker is constitutively expressed. In 107 
this common backbone different antibiotic resistance mutations were introduced by P1 108 
transduction. The donor strains were spontaneous antibiotic resistant mutants previously 109 
obtained by plating the sensitive bacteria in Luria-Bertani (LB) supplemented with agar and 110 
100 mg/mL of either streptomycin or rifampicin [14]. A total of eight strains were constructed: 111 
K43TStr-YFP, S531FRif-YFP, H526YRif-YFP, H526DRif-YFP and K43TStr-CFP, S531FRif-CFP, 112 
H526YRif-CFP, H526DRif-CFP, such that the same resistance allele was introduced in the two 113 
fluorescence backgrounds. K43TStr confers resistance to streptomycin and all the other 114 
aminoacid changes confer resistance to rifampicin. In order to confirm the identity of the 115 
mutations transferred by P1 transduction, the antibiotic resistance target gene (rpoB for 116 
rifampicin or rpsL for streptomycin) was amplified and sequenced using the following primers: 117 
for the relevant fragment of the rpoB gene, 5’-CGTCGTATCCGTTCCGTTGG-3’ and 5’-118 
TTCACCCGGATAACATCTCGTC-3’ and for the rpsL gene, 5’-119 
ATGATGGCGGGATCGTTG-3’ and 5’-CTTCCAGTTCAGATTTACC-3’. Each resistant 120 
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clone was grown from a single colony in LB medium supplemented with the respective 121 
antibiotic at 37ºC with aeration and stored in 15% glycerol at - 80°C.  122 
 123 
Fitness assays and test for frequency dependent selection  124 
The fitness costs of antibiotic resistance mutations were first measured in competition against 125 
a sensitive reference strain (Table S1). The reference strain carried a yfp allele if the resistant 126 
strain carried the cfp allele (and vice versa). Competitions were done after acclimatization, 127 
where each bacterial strain was grown in the same environment of the competition: in a 96 well 128 
plate with 150µL of LB per well at 37°C with aeration.  Acclimatization consisted of two 129 
consecutive passages where 5μL from the first 24 hour grown culture were used to inoculate a 130 
new plate for another 24h. Competitions were performed by inoculating ~105 cells of both 131 
competitor and reference strain in LB medium and allowed to grow for 24 hours (~9 132 
generations). The initial and final ratios of both strains were determined by Flow Cytometry. 133 
Fitness effects of the resistance mutations were estimated as the slope between 0 and 24h of the 134 
ln(f(NR)/(1-f(NR))), where f(NR) is the frequency of resistant bacteria in the population or one 135 
of the reference resistance backgrounds, in the case of the competitions of the evolved clones.  136 
H526YRif and H526DRif strains were tested for negative frequency dependent selection in the 137 
same conditions as described above, and the number of cells was measured using the Flow 138 
Cytometer BD LSR Fortessa (BD Biosciences), at different initial ratios of the two strains: 139 
100:1, 10:1, 1:1, 1:10 and 1:100 (H526YRif:H526DRif). 140 
 141 
Long-term propagation of resistant populations  142 
Prior to the start of the long-term competitions, acclimatization of the bacterial strains was 143 
performed in plates with a checkered arrangement (one plate for YFP strains, another for CFP 144 
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strains). Each well was inoculated with an independent starting sample, from a frozen culture, 145 
into 150l of LB medium, to maximize the probability of sampling a large pool of beneficial 146 
mutations. We note that it is possible that beneficial mutations occur during the acclimatization 147 
period, since the rate of mutations which compensate for the cost of resistance can be very high 148 
[22]. After 24 hours, 5l of the grown cultures where inoculated into fresh LB media and after 149 
48h the numbers of bacteria were measured. Appropriate dilutions were done to achieve the 150 
required initial ratio (1:1) of YFP and CFP strains for the long-term evolution of competing 151 
clones. This evolution was performed in the same conditions as the fitness assays, with daily 152 
passages of about ~105 bacteria for ~280 generations (30 days). Samples of the evolving 153 
populations were frozen every day, from which the relative abundance of each resistance was 154 
followed by measuring the frequencies of their linked fluorescent alleles by Flow Cytometry. 155 
The following three pairs of mutants were studied: K43TStr vs S531FRif, H526YRif vs H526DRif 156 
and H526YRif vs S531FRif. For each pairwise competition of mutants, 16 replicas were 157 
performed: half where one of the resistances, say R1, was linked to the yfp background and the 158 
other half where it was linked with the cfp background. Pairwise combinations of mutants (R1-159 
YPF vs R2-CFP and R1-CFP vs R2-YFP) were settled in a checkerboard arrangement (Figure 160 
1), where half of the wells were filled solely with LB to control for external contamination.  161 
 162 
Estimation of relative parameters of beneficial mutations  163 
The dynamics of a given costly resistance allele (R1) when competing with another resistant 164 
clone (R2), with a different fitness cost, were analyzed under a simple model of positive 165 
selection, that assumes the occurrence of new beneficial alleles which are sweeping towards 166 
fixation. We first fitted the simplest possible model (Model 1), which can allow for a costly 167 
resistance allele to be maintained for hundreds of generations despite its initial cost. In this 168 
 8 
model we assume an initial population composed of two distinct genotypes, with different 169 
resistances and initial fitnesses, wR1 and wR2. The initial frequency of the more costly genotype, 170 
R20, is taken from a uniform distribution within the interval R2Experimental0 ± 0.1, while that of 171 
the other genotype is R10=1-R20. At generation TN a new genotype, with fitness wN, is assumed 172 
to have arisen and reached a frequency N0=0.001. From that time onwards it is assumed to 173 
change in frequency deterministically towards fixation. Therefore, we modeled selection 174 
deterministically in discrete time with two genotypes for t<TN, and three for t>TN. We estimated, 175 
by maximum likelihood, the parameters R20, TN and wN that best fit the observed values of 176 
ln(M/(1-M)), where M is the measured frequency of a fluorescent marker, at several time points, 177 
assuming a normal distribution for  measurement error (with average 0 and standard deviation 178 
0.2). The search for the set of parameters that maximize the likelihood of the data in the space 179 
of the possible parameters was performed using the Nelder-Mead Method, as implemented in 180 
Mathematica 8.0 (http://mathworld.wolfram.com/Nelder-MeadMethod.html), with 100 181 
iterations and repeated for 100 realizations with different initial starting combinations of 182 
parameter values. While Model 1 could provide a reasonable fit for some of the replicate 183 
experimental lines, for others it did not. We therefore fitted the next simplest model (Model 2) 184 
which assumes that two beneficial mutants (N1 and N2), one for each background and 185 
fluorescent marker (with fitnesses WN1 and WN2), emerged at times (TN1 and TN2). We selected 186 
the model with the lower AIC (Akaike Information Criteria) to test if the different resistances 187 
would have distinct evolvabilities. Specifically, for each pair of competing resistances and each 188 
experimental evolved population, we asked if the times of appearance of beneficial mutations 189 
or the effects of accumulated beneficial mutations were significantly different. If the genetic 190 
target for acquiring beneficial mutations is larger for resistance background R2 than for R1, but 191 
the effects of the compensatory mutations are similar, then we expect the time of appearance of 192 
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mutations to be smaller in R2 than in R1. If the target is similar but the effects depend on the 193 
background we expect to observe a significant difference between the effects accumulated in 194 
one resistance background versus the other. The method used here is a discrete adaptation of 195 
existing methodologies to infer evolutionary parameters [54], with the added difference of 196 
allowing for different initial fitness values in competing genetic backgrounds. Code for these 197 
simulations is available upon request. The inference process and summary relative effects are 198 
shown for a single line, as an example, in Figure S1. 199 
 200 
Whole genome sequencing of H526YRif and S531FRif evolved clones 201 
A single clone of each resistance (H526YRif and S531FRif) from each evolved population was 202 
isolated in LB agar plates with rifampicin at the end of the evolution experiment. In six 203 
populations the frequency of clones from the S531FRif background was very low and no 204 
resistant clone was sampled. DNA was extracted from each sampled clone, and then pooled 205 
according to resistance background. Paired-end sequencing using Illumina MiSeq Benchtop 206 
Sequencer, with mean coverage of 207x was performed. The resulting reads were trimmed at a 207 
Phred quality score of 99.9%, and were then aligned using Escherichia coli K12 MG1655 208 
(NC_000913.2) as the reference genome. Mutation prediction was done using version 0.23 of 209 
BRESEQ pipeline 210 
(http://barricklab.org/twiki/bin/view/Lab/ToolsBacterialGenomeResequencing), with 211 
polymorphism detection on. Other settings were used as default except for: a) requirement of a 212 
minimum coverage of 3 reads on each strand per polymorphism; b) polymorphism predictions 213 
occurring in homopolymers of length greater than 3 were discarded; c) polymorphism 214 






Pairwise competitions between different AR alleles were performed in an antibiotic free 220 
environment for around 280 generations. Each strain carries a neutral fluorescence marker. 221 
Three pairs of resistance mutations were studied: 2 pairs involving 3 different Rif resistance 222 
alleles, and one pair involving a Str and a Rif resistance allele (Figure 1). The costs of each 223 
resistance allele measured against a sensitive reference strain of E. coli are shown in Table S1.  224 
The cost of resistance in relation to the sensitive is higher for the S531FRif mutation (0.1 ± 0.01) 225 
and the K43TRif mutation (0.09 ± 0.03), followed by H526YRif (0.07 ± 0.01) and H526DRif (0.06 226 
± 0.02) mutations. We then inferred the fitness cost of the same resistance mutations but this 227 
time in the presence of another resistance. Whether a resistance allele was more or less costly 228 
was estimated from the change in frequency of the fluorescent markers, linked to the resistances, 229 
during the first three days of evolution where the pairs of AR mutants were competing (Figure 230 
2, 3 and 4, and also Figure S2 for each of the replicates identified by its neutral marker). We 231 
assume that during this short period new beneficial mutations have not yet arisen, or are at a 232 
frequency too low to interfere with the relative fitness differences that both clones may have.  233 
For each pairwise evolution experiment we query whether different AR mutants show distinct 234 
adaptive potential. For that, we inferred the fitness effects of new beneficial mutations that 235 
could explain the observed long-term frequency dynamics of the AR alleles. We allowed for 236 
one or two beneficial mutations of different effects to emerge at different times, in either of the 237 
backgrounds (see Methods). We sought to infer the combination of parameters (time of 238 
emergence, effect of the beneficial mutation, and the initial frequency of one of the resistance 239 
alleles) that provided the best fit to the observed evolutionary dynamics. We started by fitting 240 
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a model where a single new beneficial mutation (with effect SN, at time TN) escapes stochastic 241 
loss in the background with lower initial fitness (Model 1). We estimated the value of SN and 242 
TN that best fits the dynamics of each resistance, under this model. We then used a model 243 
assuming that two beneficial mutations had increased in frequency, one in each background, 244 
and fitted the parameters of this second model (TN1, SN1, and TN2, SN2) to the dynamics observed. 245 
The lines shown in Figure S3 represent the model that best fits the data, and the inferred 246 
parameters are presented in Table 1, 2 and 3.  247 
 248 
Potential for adaptation causes the maintenance of high cost resistance 249 
 250 
We first studied the fate of two AR mutations, conferring resistance to the same antibiotic – Rif 251 
– and altering the same aminoacid in the β subunit of RNA polymerase: H526YRif and H526DRif. 252 
While the costs of these resistances are not statistically different when measured against a 253 
sensitive strain, their relative fitness cost differs when they compete. From the initial 254 
generations of competition between these two strains, a fitness difference of 0.074 was inferred, 255 
with strain H526YRif being highly detrimental in this competitive environment (Figure 2A, black 256 
solid line). The cost carried by strain H562YRif leads to the rapid decline in its frequency, 257 
detected in the first tens of generations. With such a relative fitness cost, it should go extinct in 258 
100 generations (as indicated by the black line). Strikingly though, H526YRif is clearly able to 259 
resist extinction in the majority of the replicate lines that were evolved. Four of the lines show 260 
a frequency too low to be reliably detected by Flow Cytometry. However, plating these 261 
populations at generation 280 allows observing the presence of fluorescent colonies of the 262 
H526YRif background at extremely low frequencies. This lack of extinction can be expected 263 
under two different scenarios: negative frequency-dependent selection and/or an ability to 264 
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access higher effect beneficial mutations. We therefore tested for a possible signature of 265 
negative frequency-dependent selection, i.e., advantage from rarity of the H526YRif mutation 266 
when competing against H526DRif. In competitions between these two backgrounds, starting 267 
with different frequencies of the H526YRif allele, no advantage from rarity can be detected 268 
(Figure S4), so frequency-dependent selection is unlikely to be responsible for the observed 269 
lack of extinction of this mutation. On the other hand, analysis of the long-term frequency 270 
dynamics revealed a significant difference between the fitness effects of the mutations inferred 271 
to have emerged, with its median difference (sH526YRif – sH526DRif) deviating from 0 (P<0.001, 272 
Wilcoxon Signed Rank Test, Figure 2B). The mean difference in fitness effects between these 273 
two genetic backgrounds was 0.07 (Table 1, Figure 2B), with H526YRif background 274 
accumulating stronger effect mutations. Regarding the times of appearance of new beneficial 275 
mutations, no significant difference was detected between the backgrounds (P=0.41, Wilcoxon 276 
Signed Rank Test, Figure 2C). When considering these results together, there is a strong 277 
indication that the mean effect of beneficial or compensatory mutations for H526YRif is higher, 278 
thus qualifying the strain with the H526YRif mutation as more evolvable than the strain with the 279 
H526DRif mutation. Such higher evolvability can explain the avoidance of extinction of 280 
background H526YRif, contrary to the a priori expectation based on its lower initial fitness.  281 
 282 
Higher evolvability of H526YRif upheld in competition with an alternative resistance 283 
 284 
We then studied the ability of the H562YRif background to outcompete a mutant bearing a 285 
resistance mutation in a different aminoacid, S531FRif. Resistance to the antibiotic rifampicin 286 
is now provided by mutations causing different aminoacid substitutions in the β subunit of RNA 287 
polymerase. . Relative to the sensitive strain, H526YRif is estimated to impose a smaller mean 288 
 13 
fitness cost than S531FRif (see Table S1), although the difference is not significant. The relative 289 
fitness difference between strains H562YRif and S531FRif inferred from their direct competition 290 
is 0.015 (Figure 3A, black solid line). All lines initially decrease in frequency, in accordance 291 
with a cost of H526YRif, but in all replicates this tendency is inverted. After generation 30, the 292 
frequency of each of the resistance background stabilizes at 50% in all populations. After 293 
generation 125, additional changes in frequency can be detected. This is expected if other 294 
arising beneficial mutations increase in frequency in one or both backgrounds. In some replicate 295 
lines one of the resistance alleles starts to increase in frequency but later decreases. This is 296 
likely the result of clonal interference [55], with multiple beneficial mutations competing 297 
amongst them. There were more replicates in which H526YRif increased in frequency than 298 
expected, even under the assumption that the initial fitness difference between the backgrounds 299 
would be negligible. At generation 280, 14 out of 16 lines have a frequency of this allele above 300 
that expected by chance (p=0.004, Binomial two-sided test), which is even more striking 301 
considering that its initial frequency is below 50% in most of the lines. This deviation suggests 302 
again differences in the adaptive potential between the resistance backgrounds.  303 
We tested for possible differences in the adaptive potential of each strain by inferring the time 304 
of appearance and fitness effects of new beneficial mutations that could explain the changes in 305 
frequency of the neutral markers (Figures 3B and 3C). The mean value for differences in fitness 306 
between the two genetic backgrounds was 0.034 (see Figure 3B and Table 2). The median of 307 
the distribution of relative effects deviates significantly from 0 (P<0.001, Wilcoxon Signed 308 
Rank test, Figure 3B). The times of appearance of the new inferred beneficial mutations, 309 
however, did not appear to be significantly different between the genetic backgrounds (P=0.3, 310 
Wilcoxon Signed Rank test, Figure 3C). The overrepresentation of the H526YRif resistance 311 
background in the evolving populations, together with this analysis, indicates that H526YRif has 312 
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a higher evolvability across different competitive contexts and therefore can be easily 313 
maintained.  314 
 315 
Potential for adaptation drives the fate of resistances to different antibiotics 316 
 317 
Differences in evolvability are expected to be larger amongst resistances affecting different 318 
genes than between alleles from the same gene. This is so because the target for beneficial 319 
mutations is expected to be more similar between mutations affecting the same function than 320 
between mutations impairing different traits. To query if the costs or the evolvabilities are 321 
determinant to the competition of resistances to distinct drugs, we studied the fate of the Str 322 
resistance allele (K43TStr) when in competition with the Rif resistance allele (S531FRif). K43TStr 323 
is estimated to impose a cost to the sensitive strain of ~0.09, which is not statistically different 324 
from the cost imposed by S531FRif. However, upon competition between these two strains, 325 
K43TStr shows a disadvantage of around 0.03 relative to S531FRif (Figure 4A, black solid line). 326 
This is observed in the initial 25 generations, where K43TStr decreases in frequency in most 327 
replicate competitions. The long-term evolutionary dynamics, however, depart from those 328 
observed in the previous studied cases. In Figure 4A, a higher variation in the outcome of which 329 
resistance wins the competition emerges in this pair of competing resistances. In the vast 330 
majority of the replicate lines the K43TStr mutation survived extinction for the duration of the 331 
experiment, contrary to what would have been expected from its initial relative fitness cost. In 332 
most of the lines, K43TStr is kept at a stable frequency of around 30% and in three lines it rises 333 
in frequency, sweeping to majority status (above 99% frequency) by generation 280. Contrary 334 
to expectations, extinction (frequency below 1%) of the more costly allele was only observed 335 
in two of the populations. Most of the lines where the K43TStr resistance was kept at a stable 336 
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but low frequency at the middle time points had different outcomes, with some rising and others 337 
decreasing in frequency. Overall, at the end of the 280 generations, the background with the 338 
K43TStr allele reached a frequency higher than 50% in 6 out of 15 evolved replicate lines. The 339 
inference of evolutionary parameters performed for the long-term dynamics indicates that there 340 
is a significant difference in the strength of mutations acquired by each background (P=0.014, 341 
Wilcoxon Signed Rank Test, Figure 4B). K43TStr acquires beneficial mutations of a stronger 342 
effect than does the background S531FRif (mean difference 0.03, Table 3). No significant 343 
difference was detected for the times of appearance of beneficial mutations between both 344 
backgrounds (P=0.6, Wilcoxon Signed Rank Test, Figure 4C). The differences inferred from 345 
the dynamics in Figure 4A therefore depart from the expectation of a non-epistatic model of 346 
beneficial mutations, where both backgrounds would access mutations of similar effect. 347 
Extinction might have been avoided for this Str resistance mutation by its ability to accumulate 348 
stronger effect mutations when competing with the Rif resistant strain. 349 
 350 
Genetic characterization and fitness determination of evolved clones isolated from the long-351 
term competition between  H526YRif and  S531FRif 352 
 353 
In the three cases of long-term competitions studied, the differences in evolvability inferred 354 
resulted from differences in the effects of the beneficial mutations acquired. We inferred that 355 
H526YRif could acquire higher effect mutations, relative to those emerging in S531FRif clones, 356 
even though these two different alleles cause very similar fitness costs. To gain further insight 357 
into the mutations acquired by the H526YRif background in this competitive context, we 358 
performed whole genome sequencing (see Methods for a description of the procedure) of a 359 
sample of H526YRif and of S531FRif clones, after these two lineages had evolved in competition 360 
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(Figure 3). Table 4 shows the mutations identified in each of the evolved backgrounds. We 361 
could identify 12 (in 10 distinct genes or intergenic regions) for possible beneficial (and 362 
compensatory) mutations in H526YRif (all single point mutations), and 10 (all in different 363 
genes/intergenic regions) in S531FRif (seven of them were single point mutations , the other 364 
three involved transpositions of insertion sequence elements). Mutations in the H526YRif 365 
background were observed at a higher frequency compared to the ones observed in S531FRif. 366 
This suggests that the mutations appearing in the H526YRif background have stronger effects, 367 
since they are acquired by different replicate evolving populations, pointing to a rapid fixation 368 
due to their beneficial effect. To enquire if this is indeed the case we performed competition 369 
assays between each individual clone and the ancestral strains. Since the whole genome 370 
sequencing was performed with a mixture of clones (see Methods) we  targeted sequencing 371 
each individual clone to gain access to the haplotypic composition of each clone. For the clones 372 
carrying the H526YRif mutation, we targeted the most prevalent mutations detected (see Table 373 
4). Fifteen out of the 16 H526YRif clones carried at least one mutation in the target genes 374 
(Supplementary Table 2) and one clone was found to have two mutations, one single point 375 
mutation in rpoA and another in waaZ. The aminoacid change T196I in rpoA was present in 8 376 
independently evolved clones. Since all of them have the same genetic background (H526YRif 377 
YFP), this suggests that this mutation could already have been present prior to the long-term 378 
evolution experiment. All S531FRif clones, except one, carried one of the previously identified 379 
mutations (Supplementary Table 2) and rpoC was also a target for beneficial mutations in this 380 
RifR background. We then measured the competitive fitness of each of these evolved clones to 381 
directly assay their fitness advantage. In order to increase in frequency during the long-term 382 
propagation, these mutants had to outcompete their ancestral and also the competitor with a 383 
different resistance background. Figure 5 shows that when competing either against their 384 
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respective ancestral or the other resistance clone, the selective effects of the evolved H526YRif 385 
clones are stronger than the selective effects of the mutations acquired by the S531FRif 386 
background. For the latter background, the mutations are advantageous against their ancestral, 387 
supporting their increase to detectable frequencies, but most are neutral or even deleterious 388 
versus the opposite H526YRif background. Remarkably, mutations in rpoA and rpoC provided 389 
the strongest competitive fitness advantages. Overall, these results therefore provide further 390 
support for the previously identified higher evolvability of the H526YRif background and 391 
strongly suggest that the H526YRif resistance may be easily maintained in populations. 392 
 393 
DISCUSSION 394 
In order to understand the relative role of cost versus evolvability in the maintenance of AR 395 
mutations we studied how subpopulations carrying different resistant alleles compete. This 396 
system mimics the composition of a population after drug exposure, where the different AR 397 
mutants co-exist at relatively high frequencies. This scenario has rarely been studied, though it 398 
possibly occurs in natural contexts, as has been observed in strains sampled from the same 399 
patient [2,45]. Here we address this situation by following the fate of pairwise combinations of 400 
different alleles conferring resistance to the same or different drugs. We observe that the cost 401 
of resistance measured in competition against the sensitive bacterium is not always a good 402 
predictor of the difference in costs between two resistance mutations, and transitivity between 403 
these two fitness measures is not always observed. Therefore, to understand why some resistant 404 
alleles are rarely segregating while others are pervasive, it is important to also measure their 405 
selective coefficients when in coexistence in addition to measure their costs against the sensitive 406 
strain.  407 
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In this work we studied two sets of mutations whose fitness costs were barely distinguishable 408 
when compared with the sensitive strain. The first set comprised 3 alleles of the same gene 409 
(H526YRif, H526DRif and S531FRif), thus conferring resistance to the same drug; the second 410 
group comprised alleles of different genes, (S531FRif and K43TStr), thus conferring resistance 411 
to different antibiotics. In the first set we found that H526YRif has a very significant cost (0.074) 412 
when competing with mutation H526DRif and it is less costly when competing with S531F 413 
(0.015), implying that, all else being equal, H526YRif should rapidly go extinct when competing 414 
with H526DRif, but do so at a slower pace when in competition with S531FRif. The long-term 415 
outcome of these competitions indicated that this does not always occur and the H526YRif allele 416 
can be maintained in both cases. The evolvability analysis undertaken suggests that the 417 
difference between H526YRif and H526DRif could be attributed to a higher mean effect of 418 
beneficial mutations accessible to H526YRif. This result was unexpected, because this pair of 419 
mutations involves the same aminoacid replacement and the different single point mutations 420 
cause a fitness defect of similar magnitude. Given this, one could expect similar evolvabilities 421 
between the resistance backgrounds [56]. The outcome of the competition between H526YRif 422 
and S531FRif (mutations in different aminoacids but again in the same gene) shows a tendency 423 
for the former to increase in frequency, and this could also be due to access of the former 424 
background to higher effect mutations, when in comparison with the latter. This observation is 425 
further supported by the different competitions between H526YRif and S531FRif clones, where 426 
competitive fitness assays showed stronger effects of the mutations acquired by H526YRif, as 427 
predicted by our theoretical analysis. The two cases of competition between different AR 428 
mutations both show a long-term advantage of the H526YRif allele, through its higher mean 429 
effect of mutations. Interestingly, H526YRif has been reported to be the second most frequent 430 
mutation, in a variety of clinical settings, among the ones that confer Rif resistance in M. 431 
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tuberculosis, even though it was also estimated that this mutation was the third mutation more 432 
costly in the same set [57,58]. This could be explained by the particularly high evolvability of 433 
this mutation. In the case of the pair of AR mutants composed of K43TStr and S531FRif, 434 
differences in evolvability were expected a priori since these mutations alter genes responsible 435 
for different cellular traits. In fact, evolution was less reproducible in this situation, with 436 
different replicates following different dynamics. Our results indicate that K43TStr acquired 437 
beneficial mutations of stronger effect than S531FRif, suggesting that their DEBM and hence 438 
their evolvability are different.  439 
 440 
The ability to access specific subsets of beneficial mutations determines how evolvable an 441 
organism is. If there were no constraints, then all genotypes, regardless of their composition or 442 
competitive context, would be able to adapt in a predictable sequence of mutational events. 443 
However, pleiotropy and epistasis may limit the access to new beneficial mutations [14,59,60], 444 
imposing different evolutionary outcomes in different genetic backgrounds, environmental 445 
conditions and/or competitive contexts. This is particularly relevant in the context of AR, as 446 
emergence of resistance mutants is fairly common. The resistant clones would presumably be 447 
driven to extinction when competing against less costly strains, in the absence of the drugs. 448 
Here we show that it is very likely that such extinction events will not occur and, instead, 449 
mutations that buffer the effects of resistance alleles will accumulate [36,49,61,62], allowing 450 
their maintenance. Our results indicate that different adaptive abilities and the access to strong 451 
effect beneficial mutations depends on the genetic background and the competitive context, 452 
determining the long-term fate of a given resistance allele. 453 
Antibiotic based treatments focus on immediate clinical results, but the adaptive potential of 454 
resistant bacteria is subtle [63,64] and we suggest it can affect their long-term fate within a host 455 
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or between hosts. An interesting recent observation suggests that the effects of mutations 456 
conferring resistance to streptomycin tend to be smaller for genotypes that are well adapted to 457 
a given environment, relative to genotypes not adapted at all [15]. This observation, along with 458 
the one we have made here, indicates that it is relevant to determine the relative roles of cost 459 
versus evolvability in other environments of special clinical relevance [65], in order to be better 460 
able to predict the evolution of pathogens carrying resistance alleles.  461 
 462 
CONCLUSIONS 463 
The frequency of antibiotic resistance constitutes an alarming concern for public health. A key 464 
factor determining the extinction or maintenance of resistance alleles is the fitness costs they 465 
may entail. High cost resistance alleles are expected to rapidly go extinct. However, this may 466 
not be an inescapable fate. If the availability of beneficial mutations is dependent on the genetic 467 
background, clones with less fit resistance alleles may also have higher evolvability, i.e. a 468 
higher potential for adaptation. If so, this will lead to the maintenance of resistances with a 469 
higher initial cost in populations. Here we perform competitions between strains of Escherichia 470 
coli, which carry resistance alleles of different costs, and estimate the relative differences in 471 
their adaptive potential. We demonstrate that costly resistance alleles can coexist with 472 
resistance alleles of lower cost for hundreds of generations, suggesting that their adaptive 473 
potential can override the initial relative cost of resistance. 474 
 475 
FUTURE PERSPECTIVE 476 
Antibiotic resistance poses an ever-increasing danger to public health, and its maintenance is 477 
the result of a multitude of processes, which require increasing evaluation. How the costs of 478 
resistance depend both on the specific resistant alleles, the environment where the bacteria grow 479 
 21 
and the ecological context to which they are exposed should lead to a better understanding on 480 
how resistance can be reduced or avoided. The ability of resistant bacteria for acquiring 481 
compensatory mutations and revert to sensitive state across environments should also be 482 
evaluated with the help of increasing powerful genomic technics. This is especially important 483 
for bacteria carrying multiple resistances as these are becoming more and more common. 484 
Assaying the ability of resistance alleles to emerge and thrive in ecologically relevant contexts, 485 
which are very likely to include several resistances competing simultaneously and multiple 486 
biotic factors will become crucial for our proper understanding of their long-term pathogenicity.  487 
 488 
EXECUTIVE SUMMARY 489 
Long-term evolution of polymorphic antibiotic resistance populations  490 
- In all three pairwise competitions studied, the more costly resistance avoided extinction 491 
with high probability. 492 
- In the majority of populations the costly resistance did not sweep to fixation.  493 
- The second most frequent rifampicin resistance mutation to segregate in natural 494 
pathogen populations (H526YRif) shows a high cost but also higher resistance to 495 
extinction, across multiple competitive contexts. 496 
Estimation of evolutionary parameters  497 
- The distribution of effects for the beneficial mutations depends on the resistance 498 
background, with more costly resistance backgrounds acquiring mutations of stronger 499 
effects. 500 
- Differences in rate of acquisition of beneficial mutations were not detected between the 501 
resistance backgrounds. 502 
Sequencing and competitive fitness of evolved populations  503 
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- Whole genome sequencing of the evolving replicate populations with the H526YRif and 504 
S531FRif competing clones revealed that the H526YRif background acquired more 505 
mutations at higher frequencies pointing towards its increased adaptive potential.  506 
- The number of targets identified for beneficial mutations was not significantly different 507 
between the resistance backgrounds, supporting the results from the theoretical analysis. 508 
- Competitive fitness assays showed that the mean effects of beneficial mutations is 509 
different between these two resistant backgrounds (H526YRif and S531FRif), as inferred 510 
from theoretical modeling. 511 
Conclusions  512 
- The initial relative difference in fitness costs between resistances is not predictive of 513 
their long tern evolution. 514 
- The long-term outcome of competitions between pairs of distinct antibiotic resistance 515 
alleles is polymorphism for resistance.   516 
- The results indicate that it is crucial to understand the ecological contexts and the 517 
adaptive potential of antibiotic resistance mutations in order to make informed clinical 518 
decisions regarding the treatment of bacterial infections.  519 
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FIGURE LEGENDS 720 
 721 
Figure 1. Testing the evolvability of different antibiotic resistances. First, polymorphic 722 
populations are created by mixing, in a 1:1 ratio, clones with two different antibiotic resistance 723 
mutations. All clones are isogenic, except for this different resistance mutation and a neutral 724 
fluorescent marker. 16 replicate populations are followed for each competition, where half of 725 
these replicates have one of the resistances linked with one of the neutral markers, while the 726 
other to the other marker. 3 different competitive scenarios were studied, between Rifampicin 727 
mutations (circles) and between Rifampicin and Streptomycin (squares). Next, populations are 728 
passaged in rich media in 96 well plates, organized in a checkered layout and separated by 729 
control wells (with media but without bacteria). Every 24 hours, all populations are passaged 730 
serially into a new 96 well plate with fresh media, during 30 days. The frequencies of the neutral 731 
markers (and hence the resistance alleles) are analyzed to unravel possible differences in the 732 
evolutionary parameters according to the resistance background. 733 
Figure 2. High evolvability of costly H526Y allows its long-term maintenance A) Long-734 
term dynamics, for 30 days (280 generations) of evolution in 15 replicates of a population 735 
composed of resistance strain H562Y and resistance strain H526D. Shown are the dynamics 736 
for the H526Y background. The slope of the black line represents the initial difference in fitness 737 
between the resistances. B) Whisker-box shows the relative fitness differences inferred for new 738 
beneficial mutations between the two resistant backgrounds, with H526Y background as a 739 
reference. C) Whisker-box shows the relative differences in time of appearance inferred for 740 
new beneficial mutations between the two resistance backgrounds. 741 
Figure 3. Different evolvabilities between Rifampicin resistance alleles A) Long-term 742 
dynamics, for 30 days (280 generations) of evolution in 16 replicates of a population composed 743 
of resistance strain H562Y and resistance strain S531F. Shown are the dynamics for the H526Y 744 
background. The slope of the black line represents the initial difference in fitness between the 745 
resistances. B) Whisker-box shows the relative fitness differences inferred for new beneficial 746 
mutations between the two resistant backgrounds, with H526Y background as a reference. C) 747 
Whisker-box shows the relative differences in time of appearance inferred for new beneficial 748 
mutations between the two resistance backgrounds. 749 
Figure 4. Differences in evolvability between Rifampicin and Streptomycin resistance 750 
alleles A) Long-term dynamics, for 30 days (280 generations) of evolution in 14 replicates of 751 
a population composed of resistance strain K43T and resistance strain S531F. Shown are the 752 
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dynamics for the K43T background. The slope of the black line represents the initial difference 753 
in fitness between the resistances. B) Whisker-box shows the relative fitness differences 754 
inferred for new beneficial mutations between the two resistant backgrounds, with K43T 755 
background as a reference. C) Whisker-box shows the relative differences in time of appearance 756 
inferred for new beneficial mutations between the two resistance backgrounds. 757 
Figure 5. Differences in selective effects of evolved clones from the competition between 758 
H526YRif and S531FRif. A) Fitness effects of selected clones evolved from the H526YRif 759 
background, when in competition with their ancestor (light bars) or against their other resistant 760 
competitor (S531FRif, dark bars). B) Fitness effects of selected clones evolved from the S531FRif 761 
background, when in competition with their ancestor (light bars) or against their other resistant 762 
competitor (H526YRif, dark bars). 763 
Figure S1. Example of the fitting process for a simulated experimental population. 764 
Experimental data, shown as blue circles, was simulated with a given set of parameters. 765 
Normally distributed noise (with mean 0 and standard deviation 0.2, shown also as error bars) 766 
was added to the experimental points. Red lines show the inferred trajectories given by simple 767 
model (one mutations) and the model assuming two mutations, with the fitness of the mutant 768 
(WN) and its time of appearance (TN) as parameters. Dotted arrows show the time at which 769 
sweeping beneficial mutants effectively change the dynamics of the resistance allele. Shown 770 
are also the calculations to obtain the relative parameters used in the distributions of relative 771 
effects and time. A) Model 1, with a single mutation. B) Model 2, with a mutation in each 772 
background, which has a lower AIC and is, therefore, chosen as the best model to explain the 773 
data. 774 
Figure S2. Long-term dynamics with the identification of the fluorescent backgrounds. 775 
Dynamics are shown as in Figure 2, but here the color of each line corresponds to the fluorescent 776 
marker of the mutation whose logarithm of the ratio is being plotted. A) Competitions between 777 
resistances H526Y and H526D. B) Competitions between resistances H526Y and S531F. C) 778 
Competitions between resistances K43T and S531F. 779 
Figure S3. Long-term dynamics from the inferred parameters for each replicate 780 
population. Inferred dynamics are shown as solid lines and experimental data is shown as full 781 
circles. A) Competitions between resistances H526Y and H526D. B) Competitions between 782 
resistances H526Y and S531F. C) Competitions between resistances K43T and S531F. 783 
Figure S4. Test for negative frequency dependence selection in competitions between 784 
resistance strains H526Y and H526D. X-axis shows the initial frequency of the H526Y strain 785 
and Y-axis shows the fitness effect inferred from the slope of the dynamics for the first 24 hours 786 
of the competition. 787 
 788 
TABLE LEGENDS 789 
 790 
Table 1. Evolutionary Parameters estimated for the competition between strains H526Y 791 
and H526D. W stands for the fitness of the emerging haplotype and T its time of appearance. 792 
Initial Freq stands for the inferred initial frequency of the H526Y background. In the cases 793 
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where only one of the backgrounds has acquired a mutation, the inferred parameters are in bold 794 
for the background where no mutation was inferred. 795 
Table 2. Evolutionary Parameters estimated for the competition between strains H526Y 796 
and S531F. The meaning of the parameters is as in Table 1. 797 
Table 3. Evolutionary Parameters estimated for the competition between strains K43T 798 
and S531F. The meaning of the parameters is as in Table 1. 799 
Table 4. Potential compensatory mutations identified in the genomes of the clones evolved 800 
in the competition between resistances H526Y and S531F 801 
Mutations were identified in the genomes of the evolved clones in comparison with a reference 802 
genome. Shown are the Single Nucleotide Polymorphisms (SNPs) or Insertion Sequence (IS) 803 
events identified in either of the backgrounds, and the frequencies at which they were detected. 804 
Mutations that occurred between genes (intergenic) are identified as such, otherwise all 805 
remaining mutations occurred within the gene indicated. The mutations previously identified 806 
to be compensatory are identified with a grey shaded cell. 807 
 808 
Table S1. Fitness costs imposed by the antibiotic resistance alleles (K43T, S531F, H526Y, 809 
H526D) measured in competition against the sensitive reference strain.  810 
Table S2. Genotypes of the evolved clones from competition between H526YRif and S531FRif 811 
 812 
